Related Experiment Video
Updated: Aug 31, 2025

An Effective Mouse Model of Unilateral Renal Ischemia-Reperfusion Injury
Published on: July 15, 2021
Role of coagulation in persistent renal ischemia following reperfusion in an animal model
Jesus H Dominguez1,2, Danhui Xie1, James M Dominguez1
1Nephrology Division, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
Abstract:
Ischemic acute kidney injury is common, deadly, and accelerates the progression of chronic kidney disease, yet has no specific therapy. After ischemia, reperfusion is patchy with early and persistent impairment in regional renal blood flow and cellular injury. We tested the hypothesis that intrarenal coagulation results in sustained renal ischemia following reperfusion, using a well-characterized model. Markedly decreased, but heterogeneous, microvascular plasma flow with microthrombi was found postischemia by intravital microscopy. Widespread tissue factor expression and fibrin deposition were also apparent. Clotting was accompanied by complement activation and inflammation. Treatment with exosomes derived from renal tubular cells or with the fibrinolytic urokinase, given 24 h postischemia when renal failure was established, significantly improved microvascular flow, coagulation, serum creatinine, and histological evidence of injury. These data support the hypothesis that intrarenal clotting occurs early and the resultant sustained ischemia is a critical determinant of renal failure following ischemia; they demonstrate that the coagulation abnormalities are amenable to therapy and that therapy results in improvement in both function and postischemic inflammation.NEW & NOTEWORTHY Ischemic renal injury carries very high morbidity and mortality, yet has no specific therapy. We found markedly decreased, heterogeneous microvascular plasma flow, tissue factor induction, fibrin deposition, and microthrombi after renal ischemia-reperfusion using a well-characterized model. Renal exosomes or the fibrinolytic urokinase, administered after renal failure was established, improved microvascular flow, coagulation, renal function, and histology. Data demonstrate that intrarenal clotting results in sustained ischemia amenable to therapy that improves both function and postischemic inflammation.
Insights
Intrarenal clotting causes sustained ischemia in acute kidney injury. Therapies like renal exosomes or urokinase, given after injury, improved blood flow, kidney function, and reduced inflammation.
Area of Science:
- Nephrology
- Vascular Biology
- Hematology
Background:
- Ischemic acute kidney injury (AKI) is a major cause of mortality and accelerates chronic kidney disease progression.
- Current treatments for ischemic AKI lack specificity, highlighting the need for novel therapeutic strategies.
- Post-ischemia reperfusion involves patchy blood flow and cellular damage, with the underlying mechanisms not fully understood.
Purpose of the Study:
- To test the hypothesis that intrarenal coagulation leads to sustained renal ischemia after reperfusion in a well-characterized AKI model.
- To investigate the potential of therapeutic interventions targeting coagulation to improve outcomes in established AKI.
Main Methods:
- Utilized a well-characterized model of ischemic acute kidney injury.
- Employed intravital microscopy to assess microvascular plasma flow and identify microthrombi.
- Measured tissue factor expression and fibrin deposition to evaluate coagulation status.
- Administered renal tubular cell-derived exosomes or urokinase 24 hours post-ischemia.
Main Results:
- Demonstrated markedly decreased and heterogeneous microvascular plasma flow with microthrombi post-ischemia.
- Observed widespread tissue factor expression and fibrin deposition, indicating intrarenal clotting.
- Showed that treatment with exosomes or urokinase significantly improved microvascular flow, reduced coagulation markers, and improved serum creatinine and kidney histology.
- Therapy also led to a reduction in postischemic inflammation.
Conclusions:
- Intrarenal coagulation is a critical factor causing sustained renal ischemia in AKI.
- Therapeutic interventions targeting coagulation abnormalities, such as exosomes or urokinase, can be effective even when administered after AKI is established.
- These findings highlight a promising therapeutic avenue for improving outcomes in ischemic AKI by addressing intrarenal clotting and subsequent sustained ischemia.

